Baroldi Joseph, EVP and Chief Business Officer at Ionis Pharmaceuticals (IONS), has filed 58 Form 4 transactions over the past year, all in a single company. The pattern is unambiguous: every open-market transaction was a sale. Across the entire period, Joseph reported zero open-market purchases and zero acquisitions, while selling approximately $6.82 million worth of IONS stock. The recent activity confirms this direction, with 11 sell-side transactions in the last six months and no buys.
The selling has been steady and substantial. On June 26, 2026, Joseph sold shares valued at $451,699, following a sale of $418,953 on April 16 and $523,205 on January 16. Smaller sales punctuated the period, including $325,059 on March 3, $167,892 the same day, and $439,364 on January 30. The largest single transaction was the January 16 sale at $523,205, while the smallest was a $2,916 sale on March 3. These open-market sales were frequently paired with option exercises (coded M) and compensation awards (coded A), which are mechanical events rather than discretionary trades. The option exercises on June 26, April 15, and March 3-4 were immediately followed by sales, a common pattern where executives exercise and sell to realize cash.
Notably, Joseph has not purchased a single share of IONS on the open market during this window. The absence of any P-coded transactions, combined with the consistent S-coded sales, indicates a clear divestment posture. The compensation awards in January 2026 (coded A, valued at $0) added shares to his holdings, but these were subsequently sold down. The overall trajectory is one of steady liquidation: roughly $6.8 million in sales against zero buys, with the most recent transactions in late June 2026 continuing the trend.
AI-assisted summary